HCW Biologics is trading at $1.63, up +6.54%, after FDA Type B meeting guidance clarified next steps for its planned first-in-human solid-tumor study of HCW11-018b.
- The company continues to target an IND filing in the first half of 2027; clinical-trial manufacturing is underway.
- The announcement was published at 9:03 a.m. ET, before the 9:49 a.m. price snapshot. The release did not report a market reaction.